Review and verify that any cosmetic products sourced or distributed comply with the manufacturers listed in the updated QUEST system.
Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.
Health professionals and stakeholders should review the safety signals linked to CAROTONE products in their signal management processes.
Marketing authorization holders (MAHs) must review and potentially update their product labeling to align with the new regulations by 11 April 2029 for products authorized before 11 May 2024.
Regulatory teams should integrate the new labeling information into their literature surveillance processes to ensure compliance and accurate communication surrounding Spikevax usage.
Healthcare organizations should review the NPRA annual report to ensure compliance with updated safety monitoring practices and adjust their reporting and signal management processes accordingly.
Regulatory requirements for daratumumab will need to be reviewed in light of the orphan designation status granted by the EMA.
Healthcare providers must implement a follow-up process for patients with identified cobalt-chrome modular neck components, monitoring for new or unexpected symptoms including pain, stiffness, or instability.
